NCT03818386 2024-06-14
NANORAD2
University Hospital, Grenoble
Phase 2 Unknown
Clinical Trials
150 trialsNCT05638451 2024-06-05
Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients
Zhujiang Hospital
Phase 2 Unknown
NCT03666559 2024-02-29
AGIR
Assistance Publique - Hôpitaux de Paris
Phase 2 Unknown
NCT04197492 2024-01-05
Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas
Huashan Hospital
Phase 2 Unknown
NCT03620032 2023-12-06
DIPG
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT05812534 2023-11-18
CBC
Second Affiliated Hospital of Nanchang University
Phase 2 Unknown
NCT03951142 2023-11-01
ImPRESS
Oslo University Hospital
Phase 2 Unknown
NCT04801953 2023-10-19
Nimodipine in Vestibular Schwanommas
Medical University of Vienna
Phase 2 Unknown
NCT04671459 2023-06-28
TaRRGET
Prof. Franciszek Lukaszczyk Memorial Oncology Center
Phase 2 Unknown
NCT04223999 2023-06-06
OptimalTTF-2
University of Aarhus
Phase 2 Unknown
NCT05885399 2023-06-02
The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05885386 2023-06-01
A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05883085 2023-05-31
A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL
Peking Union Medical College Hospital
Phase 2 Unknown
NCT02137759 2023-05-06
MRSI to Predict Response to RT/TMZ ± Belinostat in GBM
Emory University
Phase 2 Unknown
NCT05810350 2023-04-13
Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles
Three Gorges Hospital of Chongqing University
Phase 2 Unknown
NCT03561259 2023-02-16
OPTIMUM
Jubilant DraxImage Inc.
Phase 2 Unknown
NCT04211090 2022-11-16
CAP-BRAIN
Sun Yat-sen University
Phase 2 Unknown
NCT05611645 2022-11-10
Low-dose Bevacizumab With HSRT vs BVZ Alone for GBM at First Recurrence
Huashan Hospital
Phase 2 Unknown
NCT03071874 2022-10-18
Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas
Massachusetts General Hospital
Phase 2 Unknown
NCT05018702 2022-06-01
ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases
Fudan University
Phase 2 Unknown
NCT05385185 2022-05-23
Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer
Hebei Medical University
Phase 2 Unknown
NCT00075387 2022-05-03
Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors
OHSU Knight Cancer Institute
Phase 2 Unknown
NCT05092802 2022-05-03
The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment
Shanghai Henlius Biotech
Phase 2 Unknown
NCT04334330 2022-05-02
Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China
Sun Yat-sen University
Phase 2 Unknown
NCT05326425 2022-04-20
Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI.
Seoul St. Mary's Hospital
Phase 2 Unknown
NCT05177185 2022-02-16
HiSparCK
Ottawa Hospital Research Institute
Phase 2 Unknown
NCT03801200 2022-02-08
Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC
Hubei Cancer Hospital
Phase 2 Unknown
NCT05207904 2022-01-26
Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases
Sun Yat-sen University
Phase 2 Unknown
NCT03400917 2021-12-16
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma
Aivita Biomedical, Inc.
Phase 2 Unknown
NCT04888611 2021-11-30
Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma
Huashan Hospital
Phase 2 Unknown
NCT05133349 2021-11-24
EASOAIPPGL
Nanjing First Hospital, Nanjing Medical University
Phase 2 Unknown
NCT05125666 2021-11-18
Efficacy of Dual Task Training on Children With Ataxia After Medulloblastoma Resection
Cairo University
Phase 2 Unknown
NCT02743429 2021-10-04
Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma
University Medicine Greifswald
Phase 2 Unknown
NCT03932981 2021-09-10
TEMOTRAD01
Assistance Publique - Hôpitaux de Paris
Phase 2 Unknown
NCT02736513 2021-09-02
Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases
Soroka University Medical Center
Phase 2 Unknown
NCT04978753 2021-07-27
the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT04760431 2021-06-02
TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT04905550 2021-06-02
Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC
Chongqing University Cancer Hospital
Phase 2 Unknown
NCT02185352 2021-05-07
A-Plus
National Taiwan University Hospital
Phase 2 Unknown
NCT04874506 2021-05-05
MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)
Matrix Biomed, Inc.
Phase 2 Unknown
NCT04833205 2021-04-20
Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer
Hebei Medical University
Phase 2 Unknown
NCT04822805 2021-03-30
A Study of Anlotinib in the Treatment of Recurrent High-grade Glioma
First People's Hospital of Hangzhou
Phase 2 Unknown
NCT04801342 2021-03-17
Neurocognitive Outcome of Bilateral or Unilateral Hippocampal Avoidance WBRT With Memantine for Brain Metastases
National Taiwan University Hospital
Phase 2 Unknown
NCT04715620 2021-01-20
Niraparib Combined With Radiotherapy in rGBM
Tianjin Huanhu Hospital
Phase 2 Unknown
NCT04675008 2021-01-05
Central Nervous System(CNS) Efficacy of Dacomitinib
Samsung Medical Center
Phase 2 Unknown
NCT04674527 2020-12-19
Pilot Study of Elemene in Treating Patients With Refractory Glioblastoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT04668508 2020-12-16
Anlotinib to Malignant Brainstem Glioma
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT04583020 2020-11-30
Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04643847 2020-11-25
A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases
First People's Hospital of Hangzhou
Phase 2 Unknown
NCT04588987 2020-10-19
Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma
Sun Yat-sen University
Phase 2 Unknown